Journal: Nature Communications

Article Title: Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway

doi: 10.1038/s41467-020-20154-8

Figure Lengend Snippet: a Survival of Pdx1-Cre;Kras G12D/+ ;Gpx4 −/− (KCG) or Pdx1-Cre;Kras G12D/+ ; Gpx4 −/− ;Tmem173 −/− (KCGT) mice with or without control IgG or anti-8-OHG antibody treatment ( n = 10 mice/group; log-rank [Mantel–Cox] test). b Pancreatic weight of the indicated mice (6 months; n = 5 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). c Representative pancreas histology of the indicated mice. d Percentages of histological structures in the pancreas of the indicated mice ( n = 5 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). e Representative images of immunofluorescence staining of macrophages (red) in pancreas in indicated mice at the age of 3 months. f Relative gene expression in the pancreas of the indicated mice ( n = 3 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). g Percentage of abnormal telomeres by FISH analysis in ductal cells from KCG and KCGT mice at 3 months of age ( n = 5 mice/genotype). h mRNA expression of Tmem173 in indicated mice at 3 months of age with or without clophosome treatment ( n = 3 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). Data in b , d , and f – h are presented as mean ± SD. Data are from two or three independent experiments.

Article Snippet: To study the effects of 8-OHG inhibition on pancreatic tumorigenesis, 4–6 weeks old indicated that mice were randomly allocated into groups and injected i.p. with mouse monoclonal anti-8-OHG antibody (10 mg/kg; #GTX41980, RRID:AB_10732443, GeneTex) and control IgG2B (10 mg/kg; #MAB004, RRID:AB_357346, R&D Systems) per week for 12 weeks.

Techniques: Control, Immunofluorescence, Staining, Gene Expression, Expressing

Journal: Scientific Reports

Article Title: HIV induces airway basal progenitor cells to adopt an inflammatory phenotype

doi: 10.1038/s41598-021-82143-1

Figure Lengend Snippet: HIV-induced BC expression of IL-8 mediates AM and neutrophil migration. BC were exposed to HIV or heat-inactivated HIV for 2 days. ( A ) Quantification of IL-8 in culture supernatants of untreated, heat-inactivated HIV and HIV- treated BC cultures by ELISA. ( B ) HIV-induced BC release of these mediators induce migration of human alveolar macrophages and neutrophils. Alveolar macrophages obtained from an HIV negative normal subject were plated in serum-free medium in the upper chamber and incubated with BC-conditioned media from untreated, NL4-3 treated and heat-inactivated NL4-3-treated BC culture in the lower chamber of transwell system. The number of migratory cells were quantified after 3 h. ( C ) Migration of human alveolar macrophages mediated by BC-release of IL-8. BC-conditioned media were pre-treated with mouse IgG1 control or anti-IL-8 neutralizing antibody (both at 2 µg/ml) for 30 min prior to addition to the lower chamber. Human alveolar macrophages were plated on the upper chamber and incubated with conditioned media from untreated BC, HIV-BC pretreated with mouse IgG 1 -treated or HIV-BC pretreated with anti-IL-8 neutralizing antibody. The number of migratory alveolar macrophages were counted after 3 h. Data shown are the mean ± SD of one representative of three independent experiments performed in triplicate. ( D ) Stimulation of migration of neutrophils. Human neutrophils in serum-free RPMI were plated in the upper chamber and incubated with BC-conditioned media from untreated, HIV-treated and heat-inactivated HIV-treated BC culture in the lower chamber of transwell system. The number of migratory cells were quantified after 1 h of incubation. ( E ) Migration of human neutrophils mediated by BC-released IL-8 in conditioned media. BC-conditioned media were pre-treated with mouse IgG 1 control and anti-IL-8 neutralizing antibody (both at 2 µg/ml) for 30 min prior to addition to the lower chamber. Human neutrophils were plated on the upper chamber and incubated with conditioned media from untreated BC, HIV-BC pretreated with mouse IgG 1 -treated, HIV-BC pretreated with anti-IL-8 neutralizing antibody or HIV-treated BC. The number of migratory alveolar macrophages were counted after 1 h of incubation. Data are presented as mean ± SD of one representative of three independent experiments performed in triplicate.

Article Snippet: For blocking experiments, BC-conditioned media was pre-incubated with anti-IL-8 neutralizing antibody (clone # 6217) and corresponding mouse IgG1 control (clone # 11,711; both at 2 μg/ml, endotoxin level < 0.10 EU per 1 μg of the antibody by the LAL method; R & D Systems) for 30 min at 37 oC prior to addition to the lower chamber.

Techniques: Expressing, Migration, Enzyme-linked Immunosorbent Assay, Incubation, Control

Journal: Scientific Reports

Article Title: HIV induces airway basal progenitor cells to adopt an inflammatory phenotype

doi: 10.1038/s41598-021-82143-1

Figure Lengend Snippet: HIV-treated BC release GM-CSF that stimulates AM proliferation. ( A) Quantification of GM-CSF in BC-conditioned medium by ELISA. ( B) Proliferation of human AM is partially mediated by BC-released GM-CSF in conditioned media. Alveolar macrophages in serum-free RPMI were plated in 96-well and incubated with BC-conditioned media from untreated, HIV-treated and heat-inactivated HIV-treated BC culture. RPMI and recombinant GM-CSF (20 ng/ml) serve as background and positive controls, respectively. BC-conditioned media were pre-treated with mouse IgG 1 control and anti-GM-CSF neutralizing antibody (both at 10 µg/ml) for 30 min prior to addition to the cells. Cell proliferation was measured by BrdU incorporation assay after 3 days of culture. Data represent the mean ± SD of one representative experiment (n = 3) performed in triplicate.

Article Snippet: For blocking experiments, BC-conditioned media was pre-incubated with anti-IL-8 neutralizing antibody (clone # 6217) and corresponding mouse IgG1 control (clone # 11,711; both at 2 μg/ml, endotoxin level < 0.10 EU per 1 μg of the antibody by the LAL method; R & D Systems) for 30 min at 37 oC prior to addition to the lower chamber.

Techniques: Enzyme-linked Immunosorbent Assay, Incubation, Recombinant, Control, BrdU Incorporation Assay